Parkin antibody (AA 111-140)

Catalog No. ABIN3032153

Product Details anti-Parkin Antibody

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Binding Specificity: AA 111-140

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Parkin antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF), Flow Cytometry (FACS)

Purification: Antigen affinity purified

Immunogen: A portion of amino acids 111-140 from the human protein was used as the immunogen for this Parkin antibody.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the Parkin antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:250-1:1000,Flow Cytometry: 1:10-1:50,Immunofluorescence: 1:10-1:50,IHC (Paraffin): 1:10-1:50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the Parkin antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for Parkin

Target: Parkin (PARK2) (Parkinson Protein 2, E3 Ubiquitin Protein Ligase (Parkin) (PARK2))

Alternative Name: Parkin (PARK2 Products)

Synonyms: CG10523 antibody, Dmel\\CG10523 antibody, Dpark antibody, SD01679 antibody, dpk antibody, AR-JP antibody, LPRS2 antibody, PDJ antibody, PRKN antibody, Park antibody, Prkn antibody, si:ch211-123f21.1 antibody, zgc:112390 antibody, pdr-1 antibody, PARK2 antibody, parkin antibody, parkin RBR E3 ubiquitin protein ligase antibody, Parkinson disease (autosomal recessive, juvenile) 2, parkin antibody, park antibody, PRKN antibody, Prkn antibody, prkn antibody, CpipJ_CPIJ014867 antibody, Park2 antibody

Background: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson disease identified to date. The function of Park2 is not well-known, however, it may play a role in the ubiquitin-mediated proteolytic pathway. Mutations in this gene are known to cause autosomal recessive juvenile parkinsonism. Alternative splicing of this gene produces three known products of undetermined function.

UniProt: O60260

Pathways: Autophagy, Ubiquitin Proteasome Pathway